• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Immune checkpoint inhibitors associated with risk of small intestinal cancers in patients with metastatic melanoma

byTeddy Guo
December 17, 2020
in StudyGraphics
0
Share on FacebookShare on Twitter

RELATED REPORTS

FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option

Neoadjuvant nivolumab with chemotherapy increases survival in resectable non-small-cell lung cancer

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

Tags: dermatologyImmune-checkpoint inhibitor (ICI)ipilimumabmelanomametastatic melanomaNivolumabPembrolizumab
Previous Post

Adjunctive methylprednisolone treatment for hepatitis B acute-on-chronic liver failure associated with increased survival rate

Next Post

#VisualAbstract PET Scan Adapted Approach in Primary Mediastinal Large B-Cell Lymphoma (PMBCL) using R-CHOP

RelatedReports

Oncology

FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option

July 4, 2022
Surgical site anesthetic infusion may enhance analgesia after mastectomy
Oncology

Neoadjuvant nivolumab with chemotherapy increases survival in resectable non-small-cell lung cancer

May 30, 2022
Dacomitinib may be effective in EGFR-associated lung cancer
Chronic Disease

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

May 9, 2022
#VisualAbstract: Dermatopathologists have varying perceptions on whether the overdiagnosis of different melanocytic skin lesions is a public health issue
StudyGraphics

#VisualAbstract: Dermatopathologists have varying perceptions on whether the overdiagnosis of different melanocytic skin lesions is a public health issue

April 28, 2022
Next Post
#VisualAbstract PET Scan Adapted Approach in Primary Mediastinal Large B-Cell Lymphoma (PMBCL) using R-CHOP

#VisualAbstract PET Scan Adapted Approach in Primary Mediastinal Large B-Cell Lymphoma (PMBCL) using R-CHOP

Survival greater in cervical cancer patients undergoing abdominal hysterectomy compared to minimally invasive techniques: the LACC trial

First human facial re-transplantation after graft failure and irreversible necrosis

Parents often unaware of adolescents’ suicidal thoughts

Long-term concomitant antidepressant and benzodiazepine therapy associated with an increased risk of all-cause mortality

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
  • Cognitive behavioral therapy efficacious for treatment of comorbid posttraumatic headache and posttraumatic stress disorder symptoms among US veterans
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.